S A Graf1, P A Stevenson2, L A Holmberg3, B G Till3, O W Press3, T R Chauncey1, S D Smith3, M Philip3, J J Orozco3, A R Shustov3, D J Green3, E N Libby3, W I Bensinger3, J M Pagel3, D G Maloney3, Y Zhou4, R D Cassaday3, A K Gopal5. 1. Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington Veterans Affairs Puget Sound Health Care System, Seattle, Washington Department of Medicine, University of Washington, Seattle, Washington, USA. 2. Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington Department of Biostatistics, University of Washington, Seattle, Washington, USA. 3. Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington Department of Medicine, University of Washington, Seattle, Washington, USA. 4. Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington Department of Laboratory Medicine, University of Washington, Seattle, Washington, USA. 5. Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington Department of Medicine, University of Washington, Seattle, Washington, USA agopal@uw.edu.
Abstract
BACKGROUND: High-dose therapy and autologous stem cell transplantation (ASCT) improves outcomes for patients with mantle cell lymphoma (MCL), but relapse ultimately occurs in most patients. Recently presented interim results from a phase III prospective trial suggest maintenance rituximab (MR) after ASCT for MCL improves progression-free survival (PFS). The maturation of these data and any benefit of MR on overall survival (OS) remain to be defined. PATIENTS AND METHODS: In this retrospective study, we examined a cohort of consecutive patients with MCL that underwent ASCT for MCL at our center and evaluated their outcomes according to whether they received MR after ASCT (n = 50) or did not (n = 107). MR was treated as a time-dependent covariate to account for variation in timing of its initiation. RESULTS: MR was associated with an improved PFS [hazard ratio (HR) 0.44; confidence interval (CI) (0.24-0.80), P = 0.007] and overall survival (OS; HR 0.46; CI 0.23-0.93, P = 0.03) following a multivariate adjustment for confounding factors with a median follow-up of ∼5 years. Grade 4 neutropenia was increased (34% versus 18%, P = 0.04) in the MR group, but no effect on the rate of mortality unrelated to relapse was observed. CONCLUSIONS: These data support that MR after ASCT for MCL confers a benefit in PFS and additionally suggest it may improve OS. General application of this strategy will require confirmation of benefit in prospective randomized trials.
BACKGROUND: High-dose therapy and autologous stem cell transplantation (ASCT) improves outcomes for patients with mantle cell lymphoma (MCL), but relapse ultimately occurs in most patients. Recently presented interim results from a phase III prospective trial suggest maintenance rituximab (MR) after ASCT for MCL improves progression-free survival (PFS). The maturation of these data and any benefit of MR on overall survival (OS) remain to be defined. PATIENTS AND METHODS: In this retrospective study, we examined a cohort of consecutive patients with MCL that underwent ASCT for MCL at our center and evaluated their outcomes according to whether they received MR after ASCT (n = 50) or did not (n = 107). MR was treated as a time-dependent covariate to account for variation in timing of its initiation. RESULTS: MR was associated with an improved PFS [hazard ratio (HR) 0.44; confidence interval (CI) (0.24-0.80), P = 0.007] and overall survival (OS; HR 0.46; CI 0.23-0.93, P = 0.03) following a multivariate adjustment for confounding factors with a median follow-up of ∼5 years. Grade 4 neutropenia was increased (34% versus 18%, P = 0.04) in the MR group, but no effect on the rate of mortality unrelated to relapse was observed. CONCLUSIONS: These data support that MR after ASCT for MCL confers a benefit in PFS and additionally suggest it may improve OS. General application of this strategy will require confirmation of benefit in prospective randomized trials.
Authors: B D Cheson; S J Horning; B Coiffier; M A Shipp; R I Fisher; J M Connors; T A Lister; J Vose; A Grillo-López; A Hagenbeek; F Cabanillas; D Klippensten; W Hiddemann; R Castellino; N L Harris; J O Armitage; W Carter; R Hoppe; G P Canellos Journal: J Clin Oncol Date: 1999-04 Impact factor: 44.544
Authors: Roswitha Forstpointner; Michael Unterhalt; Martin Dreyling; Hans-Peter Böck; Roland Repp; Hannes Wandt; Christiane Pott; John F Seymour; Bernd Metzner; Annette Hänel; Tanja Lehmann; Frank Hartmann; Hermann Einsele; Wolfgang Hiddemann Journal: Blood Date: 2006-08-31 Impact factor: 22.113
Authors: Martin Dreyling; Georg Lenz; Eva Hoster; Achiel Van Hoof; Christian Gisselbrecht; Rudolf Schmits; Bernd Metzner; Lorenz Truemper; Marcel Reiser; Hjalmar Steinhauer; Jean-Michel Boiron; Marc A Boogaerts; Ali Aldaoud; Vittorio Silingardi; Hanneke C Kluin-Nelemans; Joerg Hasford; Reza Parwaresch; Michael Unterhalt; Wolfgang Hiddemann Journal: Blood Date: 2004-12-09 Impact factor: 22.113
Authors: Joy Mangel; Rena Buckstein; Kevin Imrie; David Spaner; Michael Crump; Kirsty Tompkins; Marciano Reis; Bayardo Perez-Ordonez; Sanjeev Deodhare; Robert Romans; Nancy Pennell; Jean B Robinson; Karen Hewitt; Patricia Richardson; Ana Lima; Peggy Pavlin; Neil L Berinstein Journal: Semin Oncol Date: 2002-02 Impact factor: 4.929
Authors: Bruce D Cheson; Beate Pfistner; Malik E Juweid; Randy D Gascoyne; Lena Specht; Sandra J Horning; Bertrand Coiffier; Richard I Fisher; Anton Hagenbeek; Emanuele Zucca; Steven T Rosen; Sigrid Stroobants; T Andrew Lister; Richard T Hoppe; Martin Dreyling; Kensei Tobinai; Julie M Vose; Joseph M Connors; Massimo Federico; Volker Diehl Journal: J Clin Oncol Date: 2007-01-22 Impact factor: 44.544
Authors: B S Kahl; W L Longo; J C Eickhoff; J Zehnder; C Jones; J Blank; T McFarland; W Bottner; H Rezazedeh; J Werndli; H H Bailey Journal: Ann Oncol Date: 2006-06-09 Impact factor: 32.976
Authors: W Brugger; J Hirsch; F Grünebach; R Repp; P Brossart; W Vogel; H-G Kopp; M G Manz; M Bitzer; G Schlimok; M Kaufmann; A Ganser; K Fehnle; M Gramatzki; L Kanz Journal: Ann Oncol Date: 2004-11 Impact factor: 32.976
Authors: Eva Hoster; Martin Dreyling; Wolfram Klapper; Christian Gisselbrecht; Achiel van Hoof; Hanneke C Kluin-Nelemans; Michael Pfreundschuh; Marcel Reiser; Bernd Metzner; Hermann Einsele; Norma Peter; Wolfram Jung; Bernhard Wörmann; Wolf-Dieter Ludwig; Ulrich Dührsen; Hartmut Eimermacher; Hannes Wandt; Joerg Hasford; Wolfgang Hiddemann; Michael Unterhalt Journal: Blood Date: 2007-10-25 Impact factor: 22.113
Authors: Steven M Horwitz; Robert S Negrin; Karl G Blume; Sheila Breslin; Monic J Stuart; Keith E Stockerl-Goldstein; Laura J Johnston; Ruby M Wong; Judith A Shizuru; Sandra J Horning Journal: Blood Date: 2003-08-07 Impact factor: 22.113
Authors: Stephen E Spurgeon; Brian G Till; Peter Martin; Andre H Goy; Martin P Dreyling; Ajay K Gopal; Michael LeBlanc; John P Leonard; Jonathan W Friedberg; Lawrence Baizer; Richard F Little; Brad S Kahl; Mitchell R Smith Journal: J Natl Cancer Inst Date: 2016-12-31 Impact factor: 13.506
Authors: Matthew G Mei; Thai M Cao; Lu Chen; Joo Y Song; Tanya Siddiqi; Ji-Lian Cai; Leonardo T Farol; Monzr M Al Malki; Amandeep Salhotra; Ibrahim Aldoss; Joycelynne Palmer; Alex F Herrera; Jasmine Zain; Leslie L Popplewell; Robert W Chen; Steven T Rosen; Stephen J Forman; Larry Kwak; Auayporn P Nademanee; Lihua E Budde Journal: Biol Blood Marrow Transplant Date: 2017-07-18 Impact factor: 5.742
Authors: Peter A Riedell; Mehdi Hamadani; Kwang W Ahn; Carlos Litovich; Guru Subramanian Guru Murthy; Frederick L Locke; Claudio G Brunstein; Reid W Merryman; Patrick J Stiff; Attaphol Pawarode; Taiga Nishihori; Mohamed A Kharfan-Dabaja; Alex F Herrera; Craig S Sauter; Sonali M Smith Journal: Transplant Cell Ther Date: 2021-08-24
Authors: Abraham S Kanate; Ambuj Kumar; Peter Dreger; Martin Dreyling; Steven Le Gouill; Paolo Corradini; Chris Bredeson; Timothy S Fenske; Sonali M Smith; Anna Sureda; Alison Moskowitz; Jonathan W Friedberg; David J Inwards; Alex F Herrera; Mohamed A Kharfan-Dabaja; Nishitha Reddy; Silvia Montoto; Stephen P Robinson; Syed A Abutalib; Christian Gisselbrecht; Julie Vose; Ajay Gopal; Mazyar Shadman; Miguel-Angel Perales; Paul Carpenter; Bipin N Savani; Mehdi Hamadani Journal: JAMA Oncol Date: 2019-05-01 Impact factor: 31.777
Authors: Robert W Chen; Joycelynne M Palmer; Sarah Tomassetti; Leslie L Popplewell; Jessica Alluin; Pritsana Chomchan; Auayporn P Nademanee; Tanya Siddiqi; Ni-Chun Tsai; Lu Chen; Fay Zuo; Rosemarie Abary; Ji-Lian Cai; Alex F Herrera; John J Rossi; Steven T Rosen; Stephen J Forman; Larry W Kwak; Leona A Holmberg Journal: J Hematol Oncol Date: 2018-06-28 Impact factor: 17.388